Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions

被引：190
|
作者：
Hato, Tai [1 ]
Goyal, Lipika [2 ]
Greten, Tim F. [3 ]
Duda, Dan G. [1 ]
Zhu, Andrew X. [2 ]
机构：
[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA
[3] NCI, Gastrointestinal Malignancy Sect, Thorac & Gastrointestinal Oncol Branch, Bethesda, MD 20892 USA
来源：
HEPATOLOGY | 2014年 / 60卷 / 05期
基金：
美国国家卫生研究院;
关键词：
REGULATORY T-CELLS; PERCUTANEOUS ETHANOL INJECTION; SUPPRESSOR-CELLS; POSTOPERATIVE RECURRENCE; CTLA-4; BLOCKADE; LIVER; RESPONSES; PD-1; MOLECULES; HEPATITIS;
D O I：
10.1002/hep.27246
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.
引用
收藏
页码：1776 / 1782
页数：7
相关论文
共 50 条
  • [31] The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
    Ozer, Muhammet
    George, Andrew
    Goksu, Suleyman Yasin
    George, Thomas J.
    Sahin, Ilyas
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
    Lee, Yun Hua
    Tai, David
    Yip, Connie
    Choo, Su Pin
    Chew, Valerie
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [33] Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
    Wu, Yaoqiang
    Lin, Han
    You, Xia
    Guo, Taiyan
    Sun, Tingting
    Xu, Hao
    Fu, Xibo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
    Liu, Hao-Tian
    Jiang, Meng-Jie
    Deng, Zhu-Jian
    Li, Le
    Huang, Jian-Li
    Liu, Zhen-Xiu
    Li, Le-Qun
    Zhong, Jian-Hong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
    Ruff, Samantha M.
    Manne, Ashish
    Cloyd, Jordan M.
    Dillhoff, Mary
    Ejaz, Aslam
    Pawlik, Timothy M.
    CURRENT ONCOLOGY, 2023, 30 (06) : 5863 - 5875
  • [36] Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
    Machairas, Nikolaos
    Tsilimigras, Diamantis, I
    Pawlik, Timothy M.
    CANCERS, 2022, 14 (08)
  • [37] Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
    Foy, Victoria
    McNamara, Mairead G.
    Valle, Juan W.
    Lamarca, Angela
    Edeline, Julien
    Hubner, Richard A.
    CURRENT ONCOLOGY, 2023, 30 (09) : 8665 - 8685
  • [38] Immune Checkpoint Inhibitors and Glioblastoma:A Review on Current State and Future Directions
    Ser, Merve Hazal
    Webb, Mason J.
    Sener, Ugur
    Campian, Jian L.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2024, 7 (02) : 97 - 110
  • [39] Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
    Younis, Abdullah
    Gribben, John
    IMMUNO, 2024, 4 (03): : 186 - 210
  • [40] Immune checkpoint blockade in hematological malignancies: current state and future potential
    Pophali, Prateek
    Varela, Juan Carlos
    Rosenblatt, Jacalyn
    FRONTIERS IN ONCOLOGY, 2024, 14
12345